Carfilzomib weekly 20/56 mg/m², lenalidomide and dexamethasone for early relapsed refractory multiple myeloma

Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: A phase 1b study

“…These data supported the recent approval of once‐weekly carfilzomib (70 mg/m 2 ) with dexamethasone for the treatment of patients with RRMM . Other phase 1 and phase 1/2 studies have explored once‐weekly carfilzomib across the MM disease continuum, and have thus far demonstrated promising efficacy and tolerability for this schedule . These studies have explored once‐weekly carfilzomib in combination with cyclophosphamide‐dexamethasone, pomalidomide‐dexamethasone, lenalidomide‐dexamethasone, daratumumab‐dexamethasone, and daratumumab‐lenalidomide‐dexamethasone at carfilzomib doses ranging from 27 to 70 mg/m 2 .…”

“…Median PFS was not reached in either group; the lower bounds of the 95% CI for median PFS were 14.8 months (56 mg/m 2 ) and 21.1 months (70 mg/m 2 ), as compared with 23.3 months reported for twice‐weekly KRd in ASPIRE (it should be noted that length of treatment exposure differed between studies) . In a previous study of once‐weekly KRd (with carfilzomib 56 mg/m 2 ) conducted in patients with early relapsed and refractory MM (n = 28; median of 1 prior line of therapy), the ≥VGPR rate was 75% and the ≥CR rate was 36% . The 26‐month projected PFS and OS rates were 63% and 85%, respectively …”

“…In a previous study of once‐weekly KRd (with carfilzomib 56 mg/m 2 ) conducted in patients with early relapsed and refractory MM (n = 28; median of 1 prior line of therapy), the ≥VGPR rate was 75% and the ≥CR rate was 36% . The 26‐month projected PFS and OS rates were 63% and 85%, respectively …”